Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 470523, 2 pages


1Medical Oncology 1, Veneto Institute of Oncology-IRCCS, Via Gattamelata 64, 35128 Padua, Italy
2Neurosurgery Department, Padua Hospital, 35128 Padua, Italy
3Department of Neuro-Oncology, UPMC, GH Pitié-Salpétrière, 75005 Paris, France
4DBBS, National Neurological Institute C. Mondino, University of Pavia, 27100 Pavia, Italy
5Neurology Unit, National Cancer Unit, Regina Elena, 00144 Rome, Italy
6Department of Neuro-Oncology, Città della Salute e della Scienza, University of Turin, 10126 Turin, Italy
7Department of Neuro-Oncology, Hopitaux de Marseille, Marseille, France

Received 25 June 2014; Accepted 25 June 2014; Published 26 August 2014

Copyright © 2014 Giuseppe Lombardi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Lombardi, G. Corona, P. Farina et al., “Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with IDH-mutated glioma,” Journal of Clinical Oncology, vol. 32, article 5s, 2014. View at Google Scholar
  2. O. L. Chinot, W. Wick, and T. Cloughesy, “Bevacizumab for newly diagnosed glioblastoma,” The New England Journal of Medicine, vol. 370, article 2049, 2014. View at Google Scholar
  3. M. R. Gilbert, E. P. Sulman, and M. P. Mehta, “Bevacizumab for newly diagnosed glioblastoma,” The New England Journal of Medicine, vol. 370, pp. 2048–2049, 2014. View at Google Scholar
  4. R. Soffietti, E. Trevisan, L. Bertero et al., “Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology),” Journal of Neuro-Oncology, vol. 116, pp. 533–541, 2014. View at Google Scholar